1. Home
  2. CCJ vs ILMN Comparison

CCJ vs ILMN Comparison

Compare CCJ & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cameco Corporation

CCJ

Cameco Corporation

HOLD

Current Price

$102.42

Market Cap

40.4B

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$146.73

Market Cap

20.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCJ
ILMN
Founded
1987
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Medical Specialities
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.4B
20.5B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
CCJ
ILMN
Price
$102.42
$146.73
Analyst Decision
Buy
Hold
Analyst Count
6
16
Target Price
$114.38
$119.44
AVG Volume (30 Days)
3.3M
1.6M
Earning Date
02-19-2026
02-05-2026
Dividend Yield
0.17%
N/A
EPS Growth
364.36
N/A
EPS
0.87
4.46
Revenue
$2,487,042,049.00
$4,288,000,000.00
Revenue This Year
$10.40
N/A
Revenue Next Year
$8.64
$2.24
P/E Ratio
$115.47
$31.68
Revenue Growth
23.88
N/A
52 Week Low
$35.00
$68.70
52 Week High
$110.16
$153.06

Technical Indicators

Market Signals
Indicator
CCJ
ILMN
Relative Strength Index (RSI) 68.30 72.67
Support Level $90.89 $130.42
Resistance Level $95.67 $135.95
Average True Range (ATR) 3.33 3.81
MACD 1.12 0.31
Stochastic Oscillator 97.87 96.47

Price Performance

Historical Comparison
CCJ
ILMN

About CCJ Cameco Corporation

Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: